- Home
- CANF vs NURO Comparison
CANF vs NURO Comparison
Compare CANF & NURO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- NURO
- Stock Information
- Founded
- CANF 1994
- NURO 1996
- Country
- CANF Israel
- NURO United States
- Employees
- CANF N/A
- NURO N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- NURO Medical/Dental Instruments
- Sector
- CANF Health Care
- NURO Health Care
- Exchange
- CANF Nasdaq
- NURO Nasdaq
- Market Cap
- CANF 7.9M
- NURO N/A
- IPO Year
- CANF N/A
- NURO N/A
- Fundamental
- Price
- CANF $1.20
- NURO $4.42
- Analyst Decision
- CANF Strong Buy
- NURO
- Analyst Count
- CANF 2
- NURO 0
- Target Price
- CANF $14.00
- NURO N/A
- AVG Volume (30 Days)
- CANF 413.8K
- NURO 3.9K
- Earning Date
- CANF 04-29-2025
- NURO 05-14-2025
- Dividend Yield
- CANF N/A
- NURO N/A
- EPS Growth
- CANF N/A
- NURO N/A
- EPS
- CANF N/A
- NURO N/A
- Revenue
- CANF $674,000.00
- NURO $3,032,837.00
- Revenue This Year
- CANF $461.72
- NURO N/A
- Revenue Next Year
- CANF N/A
- NURO N/A
- P/E Ratio
- CANF N/A
- NURO N/A
- Revenue Growth
- CANF N/A
- NURO N/A
- 52 Week Low
- CANF $1.22
- NURO $2.66
- 52 Week High
- CANF $4.69
- NURO $4.73
- Technical
- Relative Strength Index (RSI)
- CANF 37.12
- NURO 52.25
- Support Level
- CANF $1.22
- NURO $4.26
- Resistance Level
- CANF $1.82
- NURO $4.42
- Average True Range (ATR)
- CANF 0.13
- NURO 0.06
- MACD
- CANF -0.02
- NURO -0.01
- Stochastic Oscillator
- CANF 3.13
- NURO 66.67
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).